Building a better antipsychotic: receptor targets for the treatment of multiple symptom dimensions of schizophrenia.
about
Recent progress in understanding subtype specific regulation of NMDA receptors by G Protein Coupled Receptors (GPCRs)Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and FuturePreventing olanzapine-induced weight gain using betahistine: a study in a rat model with chronic olanzapine treatmentEffective Strategies for Nurses Empowering Clients With Schizophrenia: Medication Use as a Tool in Recovery.Animal models to improve our understanding and treatment of suicidal behaviorTwo four-marker haplotypes on 7q36.1 region indicate that the potassium channel gene HERG1 (KCNH2, Kv11.1) is related to schizophrenia: a case control study.Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.Development of allosteric modulators of GPCRs for treatment of CNS disordersAlmost all antipsychotics result in weight gain: a meta-analysis.Exploring schizophrenia drug-gene interactions through molecular network and pathway modelingPsychopharmacological Practice: The DSM Versus The Brain.Drugs in development for the treatment of schizophrenia.Mechanism of action of trazodone: a multifunctional drug.Serotonin 2A receptor antagonists for treatment of schizophrenia.Quinoline- and isoquinoline-sulfonamide analogs of aripiprazole: novel antipsychotic agents?Switching to aripiprazole for the treatment of residual mutism resulted in distinct clinical courses in two catatonic schizophrenia casesClozapine: a distinct, poorly understood and under-used molecule.Ginkgo biloba leaf extract (EGb 761®) and its specific acylated flavonol constituents increase dopamine and acetylcholine levels in the rat medial prefrontal cortex: possible implications for the cognitive enhancing properties of EGb 761®.Structural abnormalities revealed by magnetic resonance imaging in rats prenatally exposed to methylazoxymethanol acetate parallel cerebral pathology in schizophrenia.Halogen bonding enhances activity in a series of dual 5-HT6/D2 ligands designed in a hybrid bioisostere generation/virtual screening protocolMultifunctional Drugs: A Novel Concept for PsychopharmacologyEradicating Suicide at Its Roots: Preclinical Bases and Clinical Evidence of the Efficacy of Ketamine in the Treatment of Suicidal Behaviors
P2860
Q27006067-C13EF67D-3105-4675-AA26-09D3A956B69CQ28394341-B551B505-F17F-48B7-B2D7-4BEF3CE322D5Q28541531-4097038D-EAA5-45EA-BF29-72FDC5D38B50Q30276915-96950A52-544A-4998-827B-AFF87F991993Q33635653-1AB4D791-1592-4FCF-ABA4-2EB8719005CCQ33933939-D0E3437A-8A04-42DE-A76F-C67C554EC5E9Q34274859-D8545FEA-6AB9-4FFB-932D-C32D4C6131F9Q34373958-1D60879A-2267-4920-9D9B-C16F28DB3F8AQ34661499-68F742BC-8516-494A-9D39-DF8EEDCB4B89Q35624956-0E4D6D9B-F361-4725-8CFD-BA4A398EFB26Q36841553-444338A6-6103-4C70-B05F-BC84AD1F4038Q37546125-DA6E4756-BB62-46AC-BDCF-E310A8E940BBQ37679880-09F2BAA7-D271-45B5-8E1B-AE3A2FB9E19DQ37899193-81837ABE-5F2D-4C09-B800-80D72B9A1F67Q38172958-AA5DD24D-59EF-447B-9D9B-3EF6EE4B5F40Q42252687-9D64905E-1696-43E1-A536-EAE4E94D5E10Q42807652-BEC5C4D3-1F10-4518-B74D-F806B162BC95Q47372291-00D19B1E-FD83-424B-B8C4-231252029ABCQ50442482-40551CDD-8EEC-4209-B87B-2E84E840276BQ56980024-E6F75D7A-8E2B-4BD4-9A2C-AB20245255ABQ57487836-032005BA-F31B-4BAB-9CD2-C8A9AA0D5758Q59138279-03E5624B-0B7F-48E3-BDC8-B5495687F633
P2860
Building a better antipsychotic: receptor targets for the treatment of multiple symptom dimensions of schizophrenia.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Building a better antipsychoti ...... m dimensions of schizophrenia.
@en
Building a better antipsychoti ...... m dimensions of schizophrenia.
@nl
type
label
Building a better antipsychoti ...... m dimensions of schizophrenia.
@en
Building a better antipsychoti ...... m dimensions of schizophrenia.
@nl
prefLabel
Building a better antipsychoti ...... m dimensions of schizophrenia.
@en
Building a better antipsychoti ...... m dimensions of schizophrenia.
@nl
P2093
P2860
P1433
P1476
Building a better antipsychoti ...... m dimensions of schizophrenia.
@en
P2093
Dennis H Kim
Matthew J Maneen
Stephen M Stahl
P2860
P2888
P356
10.1016/J.NURT.2008.10.020
P577
2009-01-01T00:00:00Z